A phase Ib study to evaluate the safety, pharmacokinetics and efficacy of sulfatinib in patients with both medullary and differentiated thyroid cancer

Trial Profile

A phase Ib study to evaluate the safety, pharmacokinetics and efficacy of sulfatinib in patients with both medullary and differentiated thyroid cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2015 According to a Chi-Med media release, the company plans to initiate this trial by the end of 2015.
    • 09 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top